A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

The findings were published last week (February 12) in Science Advances. “[This paper] is another cautionary tale about the use of CRISPR-Cas9–based gene editing for [knock-in] purposes,” remarks Ed ...

Horizon has created a library of ready-made isogenic human cell line pairs edited using CRISPR-Cas9 technology. With 10,000 gene targets available — 3,000 of them off-the-shelf — the knockout ...

This will allow quicker and easier gene knock-down experiments, for example, because having on-board Cas9 makes more room in vectors used to deliver the guide RNA to contain multiple instructions for ...

CRISPR-Cas9 genome editing exploits ... sono-gene therapy for obesity. SeqCas9, a Cas9 variant from the Streptococcus family, recognizes a simple NNG PAM with high activity and enhanced ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple ... defend against viruses. The Cas9 protein is the most widely ...

Solving CRISPR’s challenges Casgevy uses CRISPR/Cas9 to “knock out” part of a gene responsible for making fetal hemoglobin. Normally this gene, BCL11A, shuts off after birth and adult hemoglobin takes ...

This study presents an optimized CRISPR-Cas12a system for large-scale genetic screening, revealing critical genes involved in ...

Both gene knockout and knock-in ... short palindromic repeats (CRISPR)/associated protein 9 systems are common gene-editing ...

The precise insertion of DNA sequences using the homology-directed repair (HDR) pathway is one potential use of the CRISPR/Cas genome ... of toxicity and higher knock-in efficiency Comparing ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.